---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-24-000043"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:51:52.690433+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B

## Summary
- Revenue $241M vs $344M YoY; net product sales $184M (-37%).
- Revised FY2024 product sales guidance to $3.0-3.5B; cites low EU sales, deferrals, competitive US market.
- RSV vaccine mRESVIA approved by FDA, shipping since July; EMA positive opinion.
- Phase 3 data positive for combo flu+COVID and next-gen COVID vaccines; filings planned in 2024.
- David Rubenstein joins Board Aug 5; Robert Langer and Stephen Berenson retire.

## SEC filing metadata
- accession: 0001682852-24-000043
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000043/0001682852-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000043/mrna-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-24-000043
- JSON: https://secwatch.observer/filing/0001682852-24-000043.json
- Plain text: https://secwatch.observer/filing/0001682852-24-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.